Your Global Leader in Stem Cell Market Research
Edinburgh, UK, December 7, 2016 – Precious Cells is offering their employees the ultimate employee benefit unlike anything ever seen before. They will cryogenically store employees’ and their loved ones’ stem cells, for free. This means they can be used in treatment for life threatening conditions today, tomorrow and in the future. [Read more…]
RoosterBio is an innovative mesenchymal stem cell (MSC) company that is focusing on democratizing stem cell manufacturing and ushering in a new era of regenerative medicine. Â 2016 has been a massive year for the company, as it recently announced a collaboration with BioBridge Global, as well as a co-branding partnership with the global filtration, separation and purification leader, Pall Corporation. [Read more…]
New York, USA; and Melbourne, Australia; December 6, 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that MD Anderson Cancer Center (MDACC) in Texas and the United States National Institutes of Health (NIH) will fund a clinical trial combining Mesoblast’s two synergistic proprietary technologies, Mesenchymal Precursor Cell (MPC)-based expansion and ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transpl
antation in cancer patients. The trial will provide clinical data on whether the combination of these two technologies synergistically facilitates more rapid cord blood HSC engraftment for bone marrow transplant patients than can be achieved by either technology alone.
The number of allogeneic bone marrow transplants performed globally each year could be substantially increased beyond the current 30,000, for cancer and non-cancer indications, if safe and effective alternative sources of allogeneic HSCs are available, such as cord blood, for patients who cannot find a matched donor. Unfortunately, cord blood transplants are associated with prolonged engraftment times due to insufficient numbers and inadequate homing capacity of cord blood HSCs, adversely impacting their clinical outcomes. [Read more…]
Jerusalem, Israel, Tuesday, December 6, 2016 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, today announced results from its Phase 1/2 study of NiCord® for Sickle Cell Disease (SCD). The data were presented during a poster session at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, December 3-5, 2016 in San Diego, CA. [Read more…]
Recently, Biological Industries (BI) submitted a Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for purposes of moving its NutriStem® hPSC XF Medium toward being certified for clinical applications. The product is a defined, xeno-free (XF), serum-free (SF) medium that supports the growth and expansion of human induced pluripotent stem (iPS) and embryonic stem cells (ESCs). [Read more…]
